Your browser doesn't support javascript.
loading
Cost-effectiveness of Biological Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis: Implications for Clinical Practice.
Kuijper, T Martijn; Buisman, Leander R; Hazes, Johanna M; Weel, Angelique E.
Affiliation
  • Kuijper TM; Department of Rheumatology, Maasstad Hospital, and Department of Rheumatology, Erasmus MC University Medical Center, Rotterdam; kuijpert@maasstadziekenhuis.nl.
  • Buisman LR; Institute of Health Policy and Management, Erasmus University, Rotterdam.
  • Hazes JM; Department of Rheumatology, Erasmus MC University Medical Center, Rotterdam.
  • Weel AE; Department of Rheumatology, Maasstad Hospital, and Erasmus MC University Medical Center, Rotterdam, the Netherlands.
J Rheumatol ; 44(7): 965-967, 2017 07.
Article in En | MEDLINE | ID: mdl-28668812
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cost-Benefit Analysis / Antirheumatic Agents Type of study: Evaluation_studies / Health_economic_evaluation Limits: Humans Language: En Journal: J Rheumatol Year: 2017 Document type: Article Country of publication: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cost-Benefit Analysis / Antirheumatic Agents Type of study: Evaluation_studies / Health_economic_evaluation Limits: Humans Language: En Journal: J Rheumatol Year: 2017 Document type: Article Country of publication: Canada